IDEXX (IDXX) EVP exercises 7,125 & 5,405 options; sells shares

IDEXX Laboratories (IDXX): Executive Vice President reports option exercises and stock sales.

Rhea-AI Filing Summary

IDEXX Laboratories (IDXX): Executive Vice President reports option exercises and stock sales. On 11/07/2025, the officer exercised non-qualified stock options to acquire 7,125 shares at $288.78 and 5,405 shares at $505.53. The insider then sold 5,114 shares at a weighted average price of $702.2017, 1,465 shares at $703.7339, 1,468 shares at $704.8659, and 1,378 shares at $705.5448.

Following these transactions, the officer beneficially owned 21,148.9435 shares directly, plus 160 shares held indirectly jointly with spouse. Derivative holdings reported as remaining include 1,604 options. Footnotes note weighted-average sale prices with full breakdowns available upon request and prior vesting schedules for the exercised options.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 9 txns

Insider Hunt Nimrata

Role Executive Vice President

Sold 9,425 shs ($6.63M)

Approx. gross sale proceeds $6.63M

Approx. exercise cost $4.79M

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right-to-buy)	7,125	$0.00	$0.00
Exercise	Non-Qualified Stock Option (right-to-buy)	5,405	$0.00	$0.00
Exercise	Common Stock	7,125	$288.78	$2.06M
Exercise	Common Stock	5,405	$505.53	$2.73M
Sale	Common Stock	5,114	$702.2017	$3.59M
Sale	Common Stock	1,465	$703.7339	$1.03M
Sale	Common Stock	1,468	$704.8659	$1.03M
Sale	Common Stock	1,378	$705.5448	$972K
holding	Common Stock	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (right-to-buy) — 1,604 contracts (Direct); Common Stock — 21,148.9435 shares (Direct); Common Stock — 160 shares (Indirect, jointly with spouse)

Footnotes (7)

1. F1. Includes 11 shares purchased under the Issuer Employee Stock Purchase Plan on September 30, 2025.
2. F2. Represents the weighted average price of the shares sold ranging from a low of $702.00 to a high of $703.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
3. F3. Represents the weighted average price of the shares sold ranging from a low of $703.05 to a high of $703.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
4. F4. Represents the weighted average price of the shares sold ranging from a low of $704.235 to a high of $705.175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
5. F5. Represents the weighted average price of the shares sold ranging from a low of $705.26 to a high of $705.92 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
6. F6. Grant of option to buy shares of Issuer common stock that vested in four annual installments beginning February 14, 2021.
7. F7. Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IDXX's Executive Vice President report on Form 4?

Exercises of non-qualified stock options for 7,125 shares at $288.78 and 5,405 shares at $505.53, followed by multiple open-market sales on 11/07/2025.

How many IDXX shares were sold and at what prices?

Sales included 5,114 shares at $702.2017, 1,465 at $703.7339, 1,468 at $704.8659, and 1,378 at $705.5448.

What is the insider’s IDXX share ownership after the transactions?

Direct beneficial ownership is 21,148.9435 shares, plus 160 shares held indirectly jointly with spouse.

What derivative securities remain after the reported transactions?

The filing shows 1,604 non-qualified stock options remaining beneficially owned after the transactions.

Which options were exercised and what were their terms?

Options with exercise prices of $288.78 (7,125 shares; expiration 02/13/2030) and $505.53 (5,405 shares; expiration 02/13/2032) were exercised; vesting schedules are noted in footnotes.

Does the filing provide detailed per-trade price breakdowns?

Yes. Weighted-average prices are disclosed with ranges, and the insider undertakes to provide full trade-by-trade details upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/10/2025 - 05:01 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hunt Nimrata

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK ME 04092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/07/2025		M		7,125	A	$288.78	25,168.9435(1)	D
Common Stock	11/07/2025		M		5,405	A	$505.53	30,573.9435	D
Common Stock	11/07/2025		S		5,114	D	$702.2017(2)	25,459.9435	D
Common Stock	11/07/2025		S		1,465	D	$703.7339(3)	23,994.9435	D
Common Stock	11/07/2025		S		1,468	D	$704.8659(4)	22,526.9435	D
Common Stock	11/07/2025		S		1,378	D	$705.5448(5)	21,148.9435	D
Common Stock								160	I	jointly with spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right-to-buy)	$288.78	11/07/2025		M			7,125	(6)	02/13/2030	Common Stock	7,125	$0	0	D
Non-Qualified Stock Option (right-to-buy)	$505.53	11/07/2025		M			5,405	(7)	02/13/2032	Common Stock	5,405	$0	1,604	D

Explanation of Responses:

1. Includes 11 shares purchased under the Issuer Employee Stock Purchase Plan on September 30, 2025.

2. Represents the weighted average price of the shares sold ranging from a low of $702.00 to a high of $703.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

3. Represents the weighted average price of the shares sold ranging from a low of $703.05 to a high of $703.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

4. Represents the weighted average price of the shares sold ranging from a low of $704.235 to a high of $705.175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

5. Represents the weighted average price of the shares sold ranging from a low of $705.26 to a high of $705.92 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

6. Grant of option to buy shares of Issuer common stock that vested in four annual installments beginning February 14, 2021.

7. Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt	11/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.